No Data
No Data
Disc Medicine Price Target Maintained With a $85.00/Share by Cantor Fitzgerald
Disc Medicine Price Target Maintained With a $85.00/Share by Cantor Fitzgerald
Express News | Cantor Fitzgerald Reiterates Overweight on Disc Medicine, Maintains $85 Price Target
Cantor Fitzgerald Keeps Their Buy Rating on Disc Medicine (IRON)
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
Additional analyses of data from AURORA, as well as the full adult data set from BEACONUpdated data from the ongoing Phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia, including a
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel
Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), ACADIA Pharmaceuticals (ACAD) and Disc Medicine (IRON)